Tech Company Inital Public Offerings
Fate Therapeutics IPO
On 10/1/2013, Fate Therapeutics completed its IPO
Transaction Overview
Company Name
Announced On
10/1/2013
Transaction Type
IPO
Amount
$40,200,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3535 General Atomics Ct. 200
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Better Cells for Better Therapies We combine a deep understanding of hematopoietic cell biology with an unmatched expertise in programming cell function and fate. We believe the biological properties of immune cells can be modulated outside the body to impart profound therapeutic effects inside the body upon their administration to a patient.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Wolchko
Chief Scientific Officer
Daniel Shoemaker
Vice President
Sarah Cooley
VP - Bus. Development
James Beitel
VP - Bus. Development
Robert Valamehr
VP - General Counsel
Cindy Tahl
Browse more venture capital transactions:
Prev: 10/1/2013: Dataguise venture capital transaction
Next: 10/1/2013: Cydan venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. VC transactions reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs